for pesticide residues in foods to assure protection from unacceptable pesticide exposure and to strengthen health protections from pesticide risks for sensitive populations. In addition, the FQPA required the U.S. Environmental Protection Agency (U.S. EPA) to consider the cumulative effects on human health that may result from exposure to mixtures of pesticides (FQPA 1996) . In response, the U.S. EPA Office of Pesticide Programs, in consultation with the FIFRA scientific advisory panel, has developed guidelines for the cumulative risk assessment of pesticides that share a common mechanism of toxicity (U. S. EPA 2002a S. EPA , 2002d ). The approach is conceptually similar to methods developed by the U.S. EPA for estimating exposures to mixtures of dioxins and dibenzofurans using toxicity equivalence factors to normalize the toxicity (i.e., binding to the aryl hydrocarbon receptor) of each member of the group with respect to that of a single chemical (U.S. EPA 1989) .
These new cumulative risk assessment guidelines use the finding that OP pesticides share a common mechanism of toxicity, the inhibition of cholinesterase activity (Mileson et al. 1998; U.S. EPA 1999a U.S. EPA , 2001 ). The U.S. EPA has determined oral benchmark dose 10 (BMD 10 ) values based on a 10% reduction in brain cholinesterase activity compared to controls for 33 OP pesticides (U.S. EPA 2002d). These BMD 10 values can be used to calculate relative potency factors (RPFs) for cumulative risk assessments of OP pesticide exposure. RPFs are the ratio of the toxic potency of a given chemical to that of an index chemical in the cumulative assessment group. Thus, when biologic measures of internal OP pesticide dose are available, cumulative OP pesticide dose equivalents can be calculated for a population by converting individual OP pesticide doses to index chemical toxicity equivalent doses, using RPFs, and then summing them. Fenske et al. (2000) proposed that the measurement of dialkyl phosphate metabolites in children's urine has utility for estimating single OP pesticide dose ranges and thus can provide information useful to discussions of pesticide health risks. They reported that children of farmworkers were more likely than non-farmworker children to be exposed to the OP pesticides azinphos-methyl and phosmet at levels exceeding U.S. EPA chronic dietary reference doses (RfDs) .
Another vulnerable population is pregnant women and their fetuses. The present study uses the proposed U.S. EPA cumulative risk assessment guidelines (U. S. EPA 2002a S. EPA , 2002d to examine potential health risks to pregnant women participating in the CHAMACOS (Center for the Health Assessment of Mothers and Children of Salinas) study, a birth cohort study in an agricultural area. All women assessed as part of the CHAMACOS study had detectable levels of urinary OP metabolites at some point in their pregnancy, which are likely to be from a mixture of compounds with varying toxicities and use patterns (Figure 1 ). Recognizing that people living in rural communities are potentially exposed to mixtures of chemicals with varying toxicities, this study seeks to expand the work of Fenske et al. (2000) on children by evaluating pregnant women's exposure to multiple OP pesticides and assessing the cumulative risk of these exposures. Our aim is to determine whether pregnant women living in this region are potentially exposed to OP pesticides in excess of a health-protective reference value.
Materials and Methods
Study area and population recruitment. The Salinas Valley of Monterey County is an agricultural area located in northern California, a few kilometers from the Pacific Ocean. OP insecticides are used on a variety of crops, including lettuce, broccoli, cauliflower, and strawberries. This region is approximately 25 km wide and 110 km long, extending from Castroville in the north to King City in the south. The temperate climate makes agricultural production possible almost year-round.
This study is based on serial spot urine samples collected over 6 months from pregnant women participating in the CHAMACOS study, a prospective cohort study of children's environmental health. The CHAMACOS study methods have been described previously (Eskenazi et al. 2003) . Pregnant women were eligible for enrollment if they entered prenatal care between September 1999 and November 2000 at either of two community clinics in the area (Clinica de Salud del Valle de Salinas and Natividad Medical Center). At enrollment, all participants were at least 18 years of age, eligible for Medi-Cal health insurance, at less than 20 weeks' gestation, fluent in English or Spanish, and planning to deliver their child at Natividad Medical Center. Medi-Cal is California's Medicaid health care program, and eligibility is based on economic need. The CHAMACOS study population is 94% Mexican or Mexican American, with 96% of participants living within 200% of the federal poverty line (U.S. Bureau of the Census 2000). Forty-four percent of study participants performed field or other agricultural work after becoming pregnant, and 87% lived in households where at least one adult member worked in agriculture.
Informed consent was obtained from all study participants following procedures established by the institutional review boards at the University of California, Berkeley, and the Natividad Medical Center. Maternal body weight and fetal gestational age data were abstracted from study participants' medical records.
Urine collection, storage, and analysis. We collected urine samples from women twice during pregnancy, at approximately 14 weeks gestation (n = 593) and approximately 26 weeks gestation (n = 500), and after delivery (n = 493). All three urine samples were collected from 460 women. Specimens were stored at -80°C until shipment to the Centers for Disease Control and Prevention, where six nonspecific urinary OP metabolites were measured: dimethylphosphate (DMP), dimethyldithiophosphate (DMDTP), dimethylthiophosphate (DMTP), diethylphosphate (DEP), diethyldithiophosphate (DEDTP), and diethylthiophosphate (DETP). These metabolites derive from approximately 40 OP compounds, 28 of which are registered with the U.S. EPA for use in the United States, falling into the general categories of dimethyl and diethyl OP pesticides (Table 1) .
The laboratory methods for dialkyl phosphate quantification employed the isotope dilution technique combined with gas chromatography and mass spectrometry (Bravo et al. 2002) . Isotope dilution is widely regarded as the state-of-the-art technique for trace analysis with dialkyl phosphate metabolite detection limits of 1 ppb or less (Barr et al. 1999) . Creatinine concentrations in urine were determined using a commercially available diagnostic enzyme method (Vitros CREA slides; Ortho Clinical Diagnostics, Raritan, NJ).
Laboratory quality control (QC) was established by the repeat analysis of two in-house urine pools enriched with known amounts of pesticide residues whose target values and confidence limits were previously determined. An analytical run was considered "out of control" if the QC value failed to meet the requirements of the Westgard QC multirules (Westgard 2002 ). Data were not reported from runs considered "out of control." Data analysis. We statistically analyzed urinary metabolite data from only the women who provided three urine samples. We used the following reporting convention for the six dialkyl phosphate metabolites: Samples with no analytical response were considered nondetectable and were assigned a value of zero; samples with a detectable peak were reported as numerical values in micrograms per liter of Environmental Health Perspectives • VOLUME 111 | NUMBER 13 | October 2003 (DPR 2000) and toxicity (BMD 10 ). For example, total use of malathion is greater than that of oxydemeton-methyl (DPR 2000) ; however, because oxydemeton-methyl is a much more potent inhibitor of cholinesterase (i.e., malathion oral BMD 10 = 313.9 mg/kg/day vs. oxydemeton-methyl BMD 10 = 0.09 mg/kg/day), its potential hazard is much higher. To describe annual use, they were simply added to the total; for weekly use, monthly instances of these nonagricultural uses were divided by four and added to the agriculture use information.
The PUR data we used for dose estimation were concurrent with the year in which urine samples were collected. Two factors support our choice to use annual data to represent the mixtures, rather than daily, weekly, monthly, or other time periods more proximate to the urine collection. First, the annual PUR data are more likely to approximate mixtures across all sources and times. Second, mapping of PUR data in the Salinas Valley reveals that pesticide use is relatively uniform and that there are no apparent "hot spots." Dose calculations. We used two methods to estimate OP pesticide doses from the urinary metabolite concentration data. For method 1, we assumed that metabolite levels were the result of exposure to a single pesticide . For method 2, we assumed that observed metabolites were attributable to exposure to a mixture of OP pesticides that share a common mechanism of toxicity and similar dose-response curves (U.S. EPA 2001 EPA , 2002b EPA , 2002d .
Underlying our dose estimation models are the following assumptions: a) Urinary concentrations represent steady-state conditions over a 24-hr period. Under this steadystate assumption, we estimated a full day's urinary excretion of metabolites based on a spot urine sample using creatinine as an index of total daily urinary output volume. The relationship between 24-hr urine output volume and urinary creatinine is given by the following formula:
where V i is the expected 24-hr urine output volume for the ith pregnant woman (liters per day), Ccr i is the reference value for the ith pregnant woman's daily creatinine excretion (milligrams per day) (Davison et al. 1980; Davison and Noble 1981; Knuppel et al. 1979) , and Cc i is the creatinine concentration in the ith woman's urine sample (milligrams per liter).
b) All (100%) of absorbed maternal OP pesticide dose is expressed in urine as diethyl and dimethyl phosphate metabolites.
c) The parent compounds of the six urinary OP metabolites depend strongly on the mixture of OP pesticides used for agriculture, structural pest control, right-of-way, or landscape purposes in the Salinas Valley. That is to say, the proportion of chemicals applied is a reasonable surrogate for the mixture of OP pesticides to which the women were exposed from all sources.
d) OP metabolite concentrations are equivalent to internal doses on a molar basis. Because each OP pesticide molecule devolves into exactly one of its possible dialkyl phosphate metabolites, the molar sum of metabolite equals the molar concentration of OP pesticide.
Method 1: single chemical approach. We calculated single dose estimates assuming 100% of the exposure was from a single diethyl or dimethyl OP pesticide. We assumed that urinary diethyl phosphate metabolites were attributable to chlorpyrifos, diazinon, or disulfoton and that dimethyl phosphate metabolites were attributable to dimethoate, malathion, methidathion, naled, or oxydemeton-methyl. These OP compounds are consistently among the most heavily used pesticides in the Salinas Valley (i.e., they account for 100% and 99% of total diethyl and dimethyl OP pesticide use, respectively), according to the California DPR's PUR (DPR 1999 (DPR , 2000 . Dose estimates were not aggregated across diethyl and dimethyl OP pesticide classes. Only the relevant metabolites for each compound were considered in the dose calculations; for example, chlorpyrifos dose calculations were based
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VOLUME 111 | NUMBER 13 | October 2003 • Environmental Health Perspectives Children's Health | Cumulative pesticide dose estimates for pregnant women upon DEP and DETP concentrations only (Table 1) . This method provides a reasonable upper-bound estimate of dose from exposure to specific chemicals, and it is consistent with current regulatory methods. Dose estimates from single diethyl and dimethyl OP pesticides were calculated with the following equations:
For diethyls,
For dimethyls,
where D Diethyl is the dose from diethyl OP pesticide (micrograms per kilogram per day), D Dimethyl is the dose from dimethyl OP pesticide (micrograms per kilogram per day), C is the urinary dialkyl phosphate metabolite concentration (micrograms per liter), MW DiMet_OP is the molecular weight of a dimethyl OP pesticide (grams per mole), MW DiEt_OP is the molecular weight of a diethyl OP pesticide (grams per mole), Cr Ex is the expected daily urinary creatinine excretion (milligrams per day) from reference values for pregnant women (Davison and Noble 1981; Davison et al. 1980; Knuppel et al 1979) , Cr Conc is the creatinine concentration (milligrams per liter) derived from urine samples, and BW is the pregnant woman's body weight (kilograms) around the time of urine sample collection. Reported average doses are the arithmetic means of three single-day dose estimates (creatinine adjusted) based on urine samples collected from participants twice during pregnancy and once postpartum.
Method 1: risk estimation. We used the U.S. EPA BMD 10 as the basis for our risk estimates. This BMD 10 has been developed for ingestion of OP pesticides and is based on dose-response data for brain cholinesterase inhibition in female rats representing a 10% change in enzyme levels compared with controls, derived from laboratory studies that lasted 21 days or longer (U. S. EPA 2002a S. EPA , 2002b S. EPA , 2002d The U.S. EPA is developing BMDs as an alternative to the no-observable-adverse-effect level (NOAEL) and lowest-observableadverse-effect level as points of departure for deriving RfDs for noncancer risk assessments because they use all points on the doseresponse curve, are less sensitive to the number of animals used in a study, and do not depend on dose spacing. The hazard quotient, defined as the ratio of an observed dose to an RfD, is used to express risk relative to an RfD. In contrast to the hazard quotient, the U.S. EPA uses a margin of exposure (MOE), the ratio of a point of departure (i.e., BMD) to an observed dose, to express risk using the BMD. Although an acceptable hazard quotient should be less than 1, an acceptable MOE should be significantly greater than 1, typically 100 or more, depending on the health end point and the quality and source of data used to obtain the BMD.
We selected a health-protective dose for our population based on the U.S. EPA oral BMD 10 and an MOE of 100. Thus, the dose exceeding the BMD 10 divided by 100 is a dose of concern. We selected the BMD 10 as the point of departure for this analysis, and used an MOE of 100 to account for animal to human extrapolation and intrahuman variability. The point of departure is meant to represent the lowest dose with a specified response within the range of experimental data. Risk associated with lower, environmentally relevant human exposures can be extrapolated from the point of departure. Using doses exceeding the BMD 10 /100 as doses of concern permits direct comparison of our method 1 and method 2 risk estimate results.
The BMD 10 is an appropriate measure of toxic potency for cumulative risk assessments of OP pesticides because it represents the common end point and mechanism of action for the cumulative assessment group. The acute and chronic U.S. EPA RfDs for individual OP pesticides, however, are based on NOAELs found for the most sensitive end point in the most sensitive species. These RfDs and NOAELs were derived for use in single chemical assessments, and thus are not recommended for use in cumulative assessments because they may not toxicologically represent the common mechanism of action (U.S. EPA 2002a).
Method 2: chemical mixture approach. An obvious limitation to method 1 is that women are probably exposed to the mixture of pesticides in their environment, rather than to a single compound. To estimate cumulative dose from exposure to mixtures of OP pesticides, we converted each relevant pesticide into its index chemical toxicity equivalent using RPFs, which are the ratio of the toxic potency of a given chemical to that of an index chemical in the cumulative assessment group. We used U.S. EPA oral BMD 10 values for brain cholinesterase inhibition as the measure of potency in our RPF calculations, and we selected chlorpyrifos as the index compound (Table 1 ) (U.S. EPA 2002d). A complete description of the methods and rationale for this process can be found in the U.S. EPA cumulative risk assessment reports (U.S. EPA 2001 EPA , 2002a EPA , 2002b EPA , 2002d . As defined by the U.S. EPA, [4] where chemical n is a member of the cumulative assessment group, index chemical is the chemical selected as the basis for standardization of toxicity of components in a mixture, and measure of potency is the BMD 10 .
The pesticides in our cumulative assessment group are the 11 (3 diethyl and 8 dimethyl) OP pesticides commonly applied in the Salinas Valley that metabolize to dialkyl phosphate compounds (Table 1) . PUR data for this region were used to describe the likely mixture to which the women were exposed. We selected chlorpyrifos as the index chemical because a) it is a compound in our cumulative assessment group for which complete hazard assessment and dose-response information is available, b) it metabolizes into urinary dialkyl phosphate compounds, c) it is commonly used in the Salinas Valley (DPR 1999 (DPR , 2000 , and d) its measure of relative toxicity, as expressed by the BMD 10 , falls in the mid-range of BMD 10 values for the OP pesticides in our cumulative assessment group. Method 2 risk estimates based on cumulative dose equivalents are insensitive to the choice of index chemical. Using RPFs, we calculated a pregnant woman's cumulative OP pesticide dose equivalent with the following equation:
where D Cum is the cumulative dose equivalent (micrograms per kilogram per day), µMol Diethyl is total micromoles of diethyl phosphate metabolites (DEP, DETP, DEDTP) excreted over a To estimate three single-day cumulative dose equivalents (creatinine-adjusted), we used measured metabolite levels in the three urine samples obtained from all study participants. We then calculated the arithmetic mean and summarized the minimum, median, and maximum dose equivalent from these estimates. For comparison with creatinine-adjusted estimates, we calculated volume-adjusted cumulative dose equivalents using reference values for pregnant women's total daily urine output volume (Cohen 2000; Davison and Noble 1981) .
Method 2: uncertainty analysis. The parameter defining the mixture of OP pesticides to which study participants were potentially exposed is a key source of uncertainty in our assessment. To evaluate the sensitivity of the model to this parameter, we used Monte Carlo simulation software (Crystal Ball Standard Edition 2000; Decisioneering, Inc., Denver, CO) to vary the quantity of pesticides used to describe the assumed exposure mixture. We ran 5,000 simulations based on uniform sampling distributions of the weekly kilograms of pesticides applied in the CHAMACOS study area from 1999 through 2001 (DPR 1999 (DPR , 2000 (DPR , 2001 . The uniform distributions were bounded by zero and by 110% of each pesticide's maximum reported weekly quantity applied.
Method 2: cumulative risk estimation. To assess risk we compared estimated minimum, average, and maximum cumulative dose equivalents with an MOE of 100 relative to the index chemical's BMD 10 (for chlorpyrifos, this value is BMD 10 /100 = 14.8 µg/kg/day). Our intent is to imply that women with cumulative dose equivalents that exceed the index chemical's BMD 10 /100 are potentially affected. Thus, our concept of risk is the fraction of the study population with cumulative OP pesticide dose estimates above what we consider a health-protective dose (the index chemical's BMD 10 /100).
We calculated MOEs by taking the ratio of the point of departure, chlorpyrifos's BMD 10 , to the estimated minimum, average, and maximum single-day cumulative dose equivalents ( Figure 2 ). The MOE is specifically identified by the U.S. EPA Office of Pesticide Programs as an appropriate metric for characterizing risk from exposure to mixtures of OP pesticides (U.S. EPA 2002b).
Results
Urine samples were collected from pregnant women at two prenatal study visits (around 14 and 26 weeks' gestation) and after delivery; all three samples were obtained from 460 women. Summary statistics of the urinary OP metabolites for our final sample of 446 women are presented in Table 2 . Forty-two of 1,338 samples (3%) had no measurable metabolites, and we set concentrations for the six metabolites equal to zero. Among the dimethyl phosphate metabolites, the median concentrations were DMP, 1.7 µg/L; DMTP, 6.3 µg/L; and DMDTP, 0.5 µg/L. Among the diethyl phosphate metabolites, the median concentrations were DEP, 1.1 µg/L; DETP, 0.9 µg/L; and DEDTP, 0 µg/L. Overall, the dimethyl phosphate levels were higher than diethyl phosphate levels ( Table 2) . Dose calculations. Method 1: single chemical approach. Table 3 summarizes the results for the single OP pesticide dose calculations (n = 446), including geometric mean, median, and range, for this study population. We present average dose estimates calculated by taking the arithmetic mean of three single-day doses. Depending on the assumption made about the parent compound, creatinine-adjusted average dose estimates ranged from 0 to 45.7 µg/kg/day. Median dimethyl OP pesticide dose estimates ranged from 0.18 to 0.92 µg/kg/day, and median diethyl OP pesticide dose estimates ranged from 0.12 to 0.15 µg/kg/day.
Method 1: risk estimation. Depending on the choice of pesticide used in the dose calculation, we found that between 0 and 36.1% of participants had dose estimates that exceed 0.01 times the U.S. EPA BMD 10 value, which corresponds to an MOE of 100 relative to the BMD 10 (Table 3) . The large variability underscores the significance of the assumption made about which OP parent compound is responsible for the exposure. The results suggest, however, that a portion of pregnant women participating in the CHAMACOS study may have exposures exceeding a health-protective MOE for individual OP pesticides.
Method 2: chemical mixture approach. Table 4 presents summary statistics for average cumulative OP pesticide dose equivalents derived from three spot urine samples. These dose estimates are log-normally distributed and range from 0.1 to 171.4 µg/kg/day (cumulative dose equivalents). Estimated dose equivalents from only the dimethyl OP pesticides ranged from 0.1 to 171.3 µg/kg/day, and estimated dose equivalents from only the diethyl OP pesticides ranged from 0.01 to 6.6 µg/kg/day. All study participants had average cumulative dose equivalent estimates greater than zero, and the geometric mean cumulative dose equivalent estimate for this population was 4.5 [95% confidence interval (95% CI), 4.1-5.1] µg/kg/day (Table 4) . Maximum single-day cumulative dose equivalent estimates ranged from 0.3 to 507.2 µg/kg/day [geometric mean = 9.0 (95% CI, 8.0-10.1) µg/kg/day]. Minimum and median single-day cumulative dose equivalent estimates ranged from 0 to 20.6 µg/kg/day [geometric mean = 0.7 (95% CI, 0.6-0.8) µg/kg/day] and from 0 to 32.3 [geometric mean = 2.5 (95% CI, 2.2-2.7) µg/kg/day], respectively.
Spearman rank correlation analyses indicate little or no correlation between the urinary metabolite levels at the three different sampling times. Spearman R values ranged from 0.04 to 0.11. The highest correlation coefficient (R = 0.11), found between the dimethyl phosphate metabolite concentrations in samples collected at ~14 weeks and 26 weeks gestation, was statistically significant because of the large sample size (p = 0.02) but was low in magnitude. The average of the ranges in the women's urinary dialkyl 
MOE (point of departure/cumulative dose equivalent) Percent women exposed
MOEs based on maximum cumulative dose equivalents MOEs based on minimum cumulative dose equivalents MOEs based on average cumulative dose equivalents phosphate metabolite levels was 0.02 mg/L (SD = 0.05 mg/L). Because urine samples were variable and uncorrelated between sampling periods, we present the women's estimated minimum and maximum single-day cumulative dose equivalents in addition to their average cumulative dose equivalent (Figure 2 ).
For comparison with these creatinineadjusted estimates, we also generated cumulative dose equivalent estimates by adjusting for total daily urine volume based on reference values for pregnant women (Cohen 2000; Davison and Noble 1981) . Cumulative dose equivalents calculated from volume-adjusted data were highly correlated with creatinineadjusted estimates (R 2 = 0.8), and results were very similar (data not shown). The geometric mean and median volume-adjusted estimates were slightly higher than creatinine-adjusted estimates, and the percentage of pregnant women with average cumulative dose equivalents that exceeded the index chemical's BMD 10 /100 was also higher (15.9 vs. 14.8%).
Method 2: cumulative risk estimation. Figure 3 presents the distribution of average cumulative dose for the entire population in index chemical (chlorpyrifos) toxicity equivalents (micrograms per kilogram per day). We found that 14.8% of estimated cumulative dose equivalents exceeded the index chemical's BMD 10 divided by a 100-fold uncertainty factor (14.8 µg/kg/day). The percentages of pregnant women exceeding this healthprotective dose from exposure to only the dimethyl OP pesticides or only the diethyl OP pesticides were 14.1 and 0%, respectively (Table 4) . No participant had a cumulative dose equivalent estimate exceeding the chlorpyrifos point of departure (an oral BMD 10 of 1,480 µg/kg/day).
We performed additional analyses to investigate the impact of the maximum single-day cumulative dose estimate on our average cumulative dose estimates. We found that 30% of the 66 women with average cumulative dose estimates exceeding the index chemical's BMD 10 /100 had two or more single-day estimates that were greater than the BMD 10 /100. Therefore, the average cumulative dose estimates could have been shifted upward by the maximum single-day high values, if they were rare events. Extending this analysis to the entire study population, we found that 26 of 446 (5.8%) women had two or more singleday estimates greater than the index chemical's BMD 10 /100. The geometric mean of the estimated cumulative dose equivalents for this group (22.6 µg/kg/day; 95% CI, 18.8-27.1) exceeded the index chemical's BMD 10 /100 (14.8 µg/kg/day). Further, we found that 126 of 446 (28.3%) women had one single-day estimate and 294 of 446 (65.9%) women had no single-day estimate greater than the index chemical's BMD 10 /100.
We calculated MOEs for the estimated minimum, average, and maximum single-day cumulative dose equivalents. Figure 2 presents a range of MOEs at various percentiles on a logarithmic scale. An estimated 0.4, 14.8, and 34.0% of calculated margins of exposure were less than 100 for women's minimum, average, and maximum cumulative doses, respectively. An MOE of less than 100 implies that the estimated cumulative dose is greater than the point of departure divided by a 100-fold uncertainty factor (e.g., index chemical's BMD 10 /100).
The U.S. EPA is developing guidelines for formally incorporating standard uncertainty factors and FQPA safety factors into cumulative risk assessment for OP pesticides (U.S. EPA 2002c). Final consideration of the FQPA safety factor is pending (U.S. EPA 2002d).
Method 2: uncertainty analysis. Based on 5,000 simulations, the estimated average cumulative chlorpyrifos dose equivalents ranged from 0.03 to 314.9 µg/kg/day, and the population median ranged from 1.3 to 8.7 (mean = 4.3) µg/kg/day. The percentage of participants with estimated average cumulative dose equivalents exceeding the BMD 10 /100 of chlorpyrifos ranged from 1 to 34% (mean = 14%), and the 10th and 90th percentiles were 8 and 23%, respectively. Although the simulations produced dose estimates that varied substantially, the simulation averages were consistent with the method 2 point estimates presented in Table 4 .
Method 1 and 2 comparisons. As expected, the method 2 average risk estimate fell between the upper and lower risk estimates from method 1. When assessing exposure to a single pesticide (method 1), we attributed all diethyl or dimethyl OP pesticide dose to a particular compound. Because the chemicals in our cumulative assessment group have varying toxicities, when we estimate the number of people potentially exposed over the health-protective dose using method 1, we have estimates that range from the least to the greatest number Environmental Health Perspectives • VOLUME 111 | NUMBER 13 | October 2003 EPA 1999b EPA , 1999c EPA , 1999d EPA , 1999e, 2000a EPA , 2000b EPA , 2000c EPA , 2000d .
possible, given our cumulative assessment group and the observed metabolite levels. Any mixture will have a cumulative toxicity, and consequently a risk level, somewhere between these two end points.
Discussion
We estimated OP pesticide doses based on urinary OP metabolite levels using two methods. The first assumed exposure to a single pesticide; the second assumed exposure to a mixture of OP pesticides. We found that average cumulative dose equivalents for 14.8% of CHAMACOS study participants were below the MOE of 100, which was used to define a dose of concern. Our uncertainty analysis of the pesticide mixture parameter suggests that this point estimate could range from 1 to 34%. This report presents one of the first case studies using the U.S. EPA's new cumulative risk assessment framework for OP pesticides. Current U.S. EPA guidelines provide a methodology for calculating cumulative dose using traditional exposure assessment methods that track exposure from source to dose (U. S. EPA 2002a S. EPA , 2002b S. EPA , 2002d . Such models rely on source-specific environmental concentration data, behavioral factors, and route-specific absorption factors. We used only the portions of the guidelines dealing with dose aggregation because our dose estimations are based on biomonitoring data.
We used U.S. EPA BMD 10 values as the measure of toxic potency to calculate OP pesticide RPFs. These BMD 10 values were derived from dose-response curves from studies of brain cholinesterase inhibition in female rats (U.S. EPA 2002b). With the use of these methods, cumulative dose estimates, which are toxicologically equivalent to a dose of the index chemical, will vary depending on the choice of the index chemical. The risk estimates based on these doses, however, will remain consistent regardless of the index chemical chosen from our cumulative assessment group.
Both methods of dose calculation presented here introduce uncertainty due to the assumption of parent compound(s), use of creatinine to estimate 24-hr urinary metabolite excretion, and intraindividual and temporal variability. Because our assessment was based on nonspecific metabolite data, it was necessary to make assumptions about the mixture of pesticides to which each participant was exposed (i.e., the presence of urinary dialkyl phosphate metabolites indicates exposure to one or more OP pesticides but does not indicate exposure to any particular pesticide). We incorporated PUR data for the Salinas Valley into cumulative dose equivalent calculation models to quantify the assumed mixture of parent compounds that resulted in an individual's urinary OP metabolites levels.
A limitation to this analysis is our assumption that the mixture of pesticides applied in the region for agricultural, landscaping, structural pest control, or right-of-way purposes is proportional to the mixture of OP pesticides to which the women were exposed. For individuals living in rural areas, there are other sources of pesticide exposure in addition to regional pesticide applications, including diet and home pesticide use. On the basis of home visit inspections conducted during pregnancy, we found that only 7% of women stored OP pesticides in their homes and that the presence of these pesticides was not statistically correlated with urinary metabolite levels. In addition, OP pesticide residues found in the participants' house dust included compounds that are used exclusively for agriculture (e.g., oxydemeton-methyl was detected in 67% of homes). Residues of malathion, diazinon, or chlorpyrifos were found in 93% of homes, even though these compounds were identified as pesticides used in or around only 6% of homes (Bradman A. Unpublished data).
More broadly, we are assuming that the proportions of chemicals applied in the study area were a reasonable surrogate for the mixture of pesticides to which the women were exposed from all sources, including those that do not originate in the Salinas Valley. Some assumption about mixture is necessary for this analysis, and we believe that what we have proposed is a reasonable first approximation. Ideally, the assumed mixture in such analyses could be described by a complete multimedia assessment of all potential sources of pesticide exposure. In future studies, we plan to address this issue by basing cumulative OP pesticide dose equivalent estimates on chemical-specific biologic monitoring data.
In this assessment, we assumed that 100% of absorbed maternal OP pesticide dose is expressed in urine as diethyl and dimethyl phosphate metabolites. This assumption may underestimate dose because some metabolites will be excreted in other biologic media besides urine (e.g., feces). Griffin et al. (1999) reported that, on average, 93% of administered chlorpyrifos was excreted in urine as dialkyl phosphate metabolites in five adult volunteers. Although the kinetics of elimination vary among the dimethyl and diethyl phosphate metabolites, toxicologic evidence suggests that the metabolites of many OP compounds are excreted primarily, but not exclusively, in the urine (Griffin et al. 1999; Krieger and Dinoff 2000) . Further, total OP pesticide exposure may be underestimated because several OP pesticides, such as acephate, do not metabolize to any of the urinary dialkyl phosphate metabolites and are therefore not included in our exposure-dose estimates. These OP pesticides, which do not devolve into dialkyl phosphate metabolites, represent approximately 20% of total OP pesticide use in the CHAMACOS study area.
A potentially large source of variability in our models results from the urinary metabolite data themselves. For these analyses we estimated dose based on three spot urine samples collected from each study participant over a 6-month period. Thus, uncertainty due to intraindividual variability and temporal variation in dialkyl phosphate metabolite levels was introduced. To reduce this source of variability in future studies, multiple urine samples collected per day over several days are needed. Furthermore, urine samples were collected at various times throughout the day, at the convenience of the participants. The effect of this source of variability is unknown, but it is likely that both over-and underestimates of actual daily doses were generated.
Adjusting metabolite concentration data for total daily urine volume was necessary because 24-hr urine samples are impractical in community-based studies and were not collected. Although creatinine adjustment is a common interpretive step in biologic monitoring studies, its merits are debated in the scientific community (Boeniger et al. 1993) . As a point of comparison, we also generated dose estimates by adjusting for total daily urine output volume based on reference values for pregnant women from the literature. Cumulative dose estimates calculated from volume-adjusted data were highly correlated with creatinine-adjusted estimates (R 2 = 0.8) and did not substantively change our findings. Because creatinine adjustments yielded reasonable estimates for total daily urine volumes, and they are expected to account for the relative concentrations/dilutions of the urine samples, we chose to report creatinineadjusted dose estimates only.
It is also possible that these urinary metabolites represent exposure to the breakdown products of the parent compounds, rather than exposure to the OP pesticides themselves. If this were true, pesticide doses would tend to be overestimated . To date, we have found no data in the literature to indicate that this is the case for the dialkyl phosphate metabolites. In fact, the breakdown products are probably too polar to be effectively absorbed through the skin , potentially eliminating dermal absorption of the breakdown products as a contributor to the observed urinary metabolite concentrations. More research is needed on the kinetics of elimination of these compounds. Findings from one Japanese toxicologic study suggest that exposure to diethyl phosphate metabolites would predominately result in the excretion of inorganic phosphate (Imaizumi et al. 1993) . When rats were orally exposed to the diethyl phosphate metabolites DEP and DETP at a dose of 1 g/kg, DETP intensely inhibited cholinesterase in rat brain homogenate, and DEP weakly inhibited the cholinesterase activity. DEP-treated rats excreted inorganic phosphate and organic phosphate in the 24-hr urine at amounts of 53 and 13% of the dose, respectively. DETP-treated animals excreted inorganic phosphate and organic phosphate in their urine at amounts of 18 and 10% of the dose, respectively (Imaizumi et al. 1993) .
Risk evaluation of cumulative exposures would be improved by the development of suitable regulatory reference doses. Possible points of departure for cumulative risk assessment of OP pesticides include the NOAEL and BMD 10 . The U.S. EPA is refining guidelines for formally considering standard uncertainty factors and the FQPA safety factor in cumulative risk assessments of chemicals sharing a common mechanism of toxicity (U.S. EPA 2002c). Following the general methodology used to derive RfDs from NOAELs, we have applied a 100-fold uncertainty factor to the index chemical's BMD 10 to account for intra-and interspecies variability. This healthprotective dose level may not be adequately protective for this population of pregnant women, and an additional FQPA safety factor may be necessary to account for the special sensitivity of the developing fetus to OP pesticide exposure. The U.S. EPA has recently proposed applying a 3× FQPA safety factor to the RPFs for six of the eight pesticides in our cumulative assessment group (U.S. EPA 2002d). When these 3× safety factors are applied at the RPF calculation stage (as proposed), the percentage of CHAMACOS participants with cumulative exposures exceeding the BMD 10 /100 increases from 14.8 to 41.9%.
We expect the human fetus to be particularly sensitive to OP pesticide exposure because during gestation the human brain is growing and developing very rapidly. Toxicologic studies have shown that OP compounds can cross the placental and blood-brain barriers (Chanda and Pope 1996; Gupta et al. 1985; Muto et al. 1992) . As part of a prospective cohort study being conducted by the Columbia Center for Children's Environmental Health, Whyatt et al. (2003) analyzed 142 paired blood samples collected at birth from minority mothers and newborns for 29 pesticides. They reported that 8 of the 29 pesticides (including diazinon and chlorpyrifos) were detected in > 25% of the maternal and/or cord blood samples. In another study, Whyatt and Barr (2001) detected levels of dialkyl phosphate metabolites in meconium samples collected from 20 newborn infants. These findings suggest that OP pesticides are readily transferred from the mother to the developing human fetus (Perera et al. 2002) .
For this assessment, we estimated absorbed OP pesticide dose for pregnant women. To calculate fetal dose, however, a better understanding of the physiologic and pharmacokinetic processes that would determine transfer from the mother to fetus is required. Future research is needed to explore the feasibility of using physiologically based pharmacokinetic modeling to reconstruct fetal dose from maternal biologic monitoring data. Virtually no data are available regarding the absorption, metabolism, and excretion of OP pesticides in pregnant women.
In conclusion, our results suggest that a small portion of pregnant women participating in the CHAMACOS study may have cumulative OP pesticide exposures exceeding a health-protective reference value. The potential impact of these exposures to fetal health is unknown.
